Skip to main navigation Skip to search Skip to main content

A Randomized Phase II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trial)

Stony Brook University

Project: Research

Project Details

StatusFinished
Effective start/end date03/12/07 → 01/9/10

Funding

  • Pfizer Incorporated: $2,400.00